BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$27.54M
FY 2025 · Annual
Net Income
-$26.63M
FY 2025 · Annual
Income Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15.55K | 0 | 0 | 0 | 107.93K |
| Gross Profit | (15.55K) | 0 | 0 | 0 | (107.93K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.02M | 8.02M | 15.34M | 27.18M | 21.53M |
| Selling, General & Admin | 4.96M | 7.27M | 7.94M | 6.15M | 5.9M |
| Operating Expenses | 6.97M | 15.29M | 23.27M | 33.33M | 27.43M |
| Depreciation & Amortization | 15.55K | 15.27K | 15.27K | 83.9K | 107.93K |
| EBITDA | (7.1M) | (26.82M) | (23.26M) | (4.85M) | (27.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.11M) | (15.29M) | (23.27M) | (33.33M) | (27.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.21K | 136.73K | 891.21K | 288.02K | 121.42K |
| Interest Expense | 80.09K | 979 | 0 | 0 | 37.43K |
| Other Income / Expenses | (6.84M) | (11.55M) | 2.97M | 28.4M | 656.6K |
| Income Before Tax | (13.82M) | (26.84M) | (20.3M) | (4.93M) | (26.88M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.82M) | (26.84M) | (20.3M) | (4.79M) | (26.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (467.51) | (259.50) | (195.00) | (43.68) | (62.95) |
| EPS (Diluted) | (467.51) | (259.50) | (195.00) | (43.68) | (62.95) |
| 30.13K | 103.29K | 104.13K | 109.7K | 423.11K | |
| 30.13K | 103.29K | 104.13K | 109.7K | 423.11K |
BCT.TO Earnings Waterfall · TTM
TSX:BCT.TO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$30.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-12.20, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
No filings found.
How much revenue does BCT.TO generate?
BriaCell Therapeutics Corp. (BCT.TO) reported $0.00 of revenue in fiscal 2025.
Is BCT.TO profitable?
BriaCell Therapeutics Corp. (BCT.TO) reported -$26.63M of net income.
Continue the stock analysis
Jump to another research area for this company.